Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Buy
65
PAHC Quote, Financials, Valuation and Earnings
Last price:
$21.27
Seasonality move
:
4.12%
Day range:
$20.75 - $21.41
52-week range:
$12.05 - $26.55
Dividend yield:
2.26%
P/E ratio:
44.27x
P/S ratio:
0.78x
P/B ratio:
3.49x
Volume:
335.6K
Avg. volume:
335.2K
1-year change:
75.77%
Market cap:
$860.7M
Revenue:
$1B
EPS (TTM):
$0.48
Analysts' Opinion
-
Consensus RatingPhibro Animal Health has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $21.00, Phibro Animal Health has an estimated downside of -1.18% from its current price of $21.25.
-
Price Target UpsideAccording to analysts, the highest upside price target is $27.00 representing -100% upside increase from its current price of $21.25.
Fair Value
-
According to the consensus of 2 analysts, Phibro Animal Health has -1.18% downside to fair value with a price target of $21.00 per share.
PAHC vs. S&P 500
-
Over the past 5 trading days, Phibro Animal Health has underperformed the S&P 500 by -8.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Phibro Animal Health does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Phibro Animal Health has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Phibro Animal Health reported revenues of $309.3M.
Earnings Growth
-
Phibro Animal Health has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Phibro Animal Health reported earnings per share of $0.08.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
0.78x
EV / EBIT:
24.85x
EV / Revenue:
1.40x
PEG ratio (5yr expected):
1.49x
EV / Free cash flow:
100.92x
Price / Operating cash flow:
56.28x
Enterprise value / EBITDA:
15.28x
Gross Profit (TTM):
$352.1M
Return On Assets:
1.86%
Net Income Margin (TTM):
1.75%
Return On Equity:
7.41%
Return On Invested Capital:
2.43%
Operating Margin:
8.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $972.1M | $982M | $1.1B | $249.9M | $309.3M | |
| Gross Profit | $296.1M | $298.5M | $352.1M | $78.6M | $101.9M | |
| Operating Income | $71.6M | $57.3M | $81.6M | $15.7M | $25.5M | |
| EBITDA | $104.7M | $83.7M | $101.2M | $17.9M | $25.6M | |
| Diluted EPS | $0.90 | $0.37 | $0.48 | $0.03 | $0.08 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $477.2M | $508.6M | $581.7M | $586.6M | $746.2M | |
| Total Assets | $803.7M | $849M | $961.8M | $972.7M | $1.3B | |
| Current Liabilities | $166.9M | $166.6M | $167.6M | $187.7M | $233.3M | |
| Total Liabilities | $590.3M | $609.7M | $693.5M | $701.9M | $1B | |
| Total Equity | $213.3M | $239.3M | $268.4M | $270.8M | $246.8M | |
| Total Debt | $386.8M | $400.4M | $476.2M | $474.9M | $753.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.5M | $74.3M | $55.5M | $31.6M | $3.1M | |
| Cash From Investing | -$45.4M | -$88.3M | -$271.4M | -$24.9M | -$260.5M | |
| Cash From Financing | $55.7M | -$19.5M | $253.8M | -$14.7M | $276.3M | |
| Free Cash Flow | -$60.4M | $37M | $15.3M | $20.6M | -$4.7M | |
PAHC
Sector
Market Cap
$860.7M
$38.4M
Price % of 52-Week High
80.04%
45.53%
Dividend Yield
2.26%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
75.77%
-39.05%
Beta (5-Year)
0.584
0.774
Dividend yield:
2.26%
Annualized payout:
$0.48
Payout ratio:
100.64%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$22.60
200-day SMA
Buy
Level
$21.03
Bollinger Bands (100)
Sell
Level
21.48 - 24.34
Chaikin Money Flow
Buy
Level
9.6M
20-day SMA
Sell
Level
$23.28
Relative Strength Index (RSI14)
Sell
Level
40.82
ADX Line
Sell
Level
18.36
Williams %R
Neutral
Level
-78.7383
50-day SMA
Sell
Level
$22.39
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
7.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5408)
Sell
CA Score
(Annual)
Level (-0.9326)
Buy
Beneish M-Score
(Annual)
Level (-2.9361)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.9478)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Stock Forecast FAQ
In the current month, PAHC has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PAHC average analyst price target in the past 3 months is $21.00.
-
Where Will Phibro Animal Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Phibro Animal Health share price will drop to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Phibro Animal Health?
Analysts are divided on their view about Phibro Animal Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Phibro Animal Health is a Sell and believe this share price will rise from its current level to $9.00.
-
What Is Phibro Animal Health's Price Target?
The price target for Phibro Animal Health over the next 1-year time period is forecast to be $21.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is PAHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Phibro Animal Health is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PAHC?
You can purchase shares of Phibro Animal Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Phibro Animal Health shares.
-
What Is The Phibro Animal Health Share Price Today?
Phibro Animal Health was last trading at $21.27 per share. This represents the most recent stock quote for Phibro Animal Health. Yesterday, Phibro Animal Health closed at $21.25 per share.
-
How To Buy Phibro Animal Health Stock Online?
In order to purchase Phibro Animal Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
